713 related articles for article (PubMed ID: 8364277)
1. Current issues surrounding women and minorities in drug trials.
Wermeling DP; Selwitz AS
Ann Pharmacother; 1993; 27(7-8):904-11. PubMed ID: 8364277
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
3. The IRB's role in assessing the generalizability of non-NIH-funded clinical trials.
Weijer C
IRB; 1998; 20(2-3):1-5. PubMed ID: 11656912
[No Abstract] [Full Text] [Related]
4. The NIH inclusion guidelines: challenges for the future.
Rothenberg KH; Hayunga EG; Rudick JE; Pinn VW
IRB; 1996; 18(3):1-4, 12. PubMed ID: 11654407
[No Abstract] [Full Text] [Related]
5. Evolving ethical issues in selection of subjects for clinical research.
Weijer C
Camb Q Healthc Ethics; 1996; 5(3):334-45. PubMed ID: 8862821
[No Abstract] [Full Text] [Related]
6. New rules for new drugs: the challenge of AIDS to the regulatory process.
Edgar H; Rothman DJ
Milbank Q; 1990; 68(Suppl. 1):111-42. PubMed ID: 11650413
[TBL] [Abstract][Full Text] [Related]
7. Improving protection for research subjects.
Steinbrook R
N Engl J Med; 2002 May; 346(18):1425-30. PubMed ID: 11986426
[No Abstract] [Full Text] [Related]
8. Waivers proposed for emergency studies.
Wolfgang L
Science; 1995 Oct; 270(5233):25-6. PubMed ID: 7569946
[No Abstract] [Full Text] [Related]
9. Institutional review boards in the university setting: review of pharmaceutical testing protocols, informed consent and ethical concerns.
Kobasic DM
J Coll Univ Law; 1988; 15(2):185-216. PubMed ID: 11659168
[No Abstract] [Full Text] [Related]
10. Protecting research subjects--what must be done.
Shalala D
N Engl J Med; 2000 Sep; 343(11):808-10. PubMed ID: 10984573
[No Abstract] [Full Text] [Related]
11. Clinical trials integrity: a CRO perspective.
Beach JE
Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
[TBL] [Abstract][Full Text] [Related]
12. IRBs search for answers and support during a time of institutional change.
Phillips DF
JAMA; 2000 Feb; 283(6):729-30. PubMed ID: 10683041
[No Abstract] [Full Text] [Related]
13. Participation of women in clinical trials of drug therapies: a context for the controversies.
Prout MN; Fish SS
Medscape Womens Health; 2001 Oct; 6(5):1. PubMed ID: 11698923
[TBL] [Abstract][Full Text] [Related]
14. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
Gordon VM; Sugarman J; Kass N
IRB; 1998; 20(1):1-5. PubMed ID: 11655324
[No Abstract] [Full Text] [Related]
15. Federal report says protection of human subjects is threatened by numerous factors.
Maloney DM
Hum Res Rep; 1996 May; 11(5):1-3. PubMed ID: 11654438
[No Abstract] [Full Text] [Related]
16. Historical background of clinical trials involving women and minorities.
McCarthy CR
Acad Med; 1994 Sep; 69(9):695-8. PubMed ID: 8074757
[TBL] [Abstract][Full Text] [Related]
17. Proposed regulations for research involving those institutionalized as mentally infirm: a consideration of their relevance in 1995.
Levine RJ
Account Res; 1996; 4(3-4):177-86. PubMed ID: 11654513
[No Abstract] [Full Text] [Related]
18. Clinical trials face heightened scrutiny as science and commerce appear to merge.
Lorman AJ
J Biolaw Bus; 2001; 4(4):23-32. PubMed ID: 12751494
[TBL] [Abstract][Full Text] [Related]
19. Multicenter trials and subject eligibility: should local IRBs play a role?
Freedman B
IRB; 1994; 16(1-2):1-6. PubMed ID: 11652320
[No Abstract] [Full Text] [Related]
20. Current issues in clinical research and the development of new pharmaceuticals.
Goldhammer A
Account Res; 2001; 8(4):283-91. PubMed ID: 12481798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
